There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up...
Mergers and acquisitions could make a comeback with Trump headed back to Washington.
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times. It consists of the company's...
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.
Viking stock has slipped more than 20% from its peak.
All signs are pointing toward its continued success.
The company's latest presentation supports the idea that its lead program will make billions.
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.
Are we ready for the Great Obesity Drug Gold Rush of the 2020s?